Point72 Asset Management
SNDX icon

Point72 Asset Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Point72 Asset Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-200,000
Closed -$2.46M – 2582
2025
Q1 		$2.46M Buy
200,000
+68,600
+52% +$968K 0.01% 1182
2024
Q4 		$1.74M Buy
+131,400
New +$2.25M ﹤0.01% 1292
2024
Q3 		– Sell
-62,500
Closed -$1.28M – 2314
2024
Q2 		$1.28M Buy
+62,500
New +$1.31M ﹤0.01% 1208

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Point72 Asset Management's SNDX Position: Q2 2026 in Review

Point72 Asset Management sold out of Syndax Pharmaceuticals (SNDX) in Q2 2026, closing a stake of 1,985,547 shares — an estimated $46.4M sold.

Point72 Asset Management first reported a position in SNDX in Q1 2017 and held it in 24 quarters. The position peaked at $103M in Q4 2025. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Point72 Asset Management reported no remaining Syndax Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Point72 Asset Management sold 1,985,547 Syndax Pharmaceuticals shares in Q2 2026, an estimated $46.4M.
  • Point72 Asset Management first reported a position in Syndax Pharmaceuticals in Q1 2017 and held it in 24 quarters.
  • Point72 Asset Management's Syndax Pharmaceuticals position peaked at $103M in Q4 2025.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.